Origin site-based staging system of sinonasal inverted papilloma for application to endoscopic sinus surgery

Yifan Meng MD1† | Gaoli Fang MD2† | Xiangdong Wang MD1 | Xiaohong Song MD1
Kuiji Wang MD1 | Hongfei Lou MD1 | Wenyu She MD3 | Long Qin BS4 | Mei Lv MD5
Tao Zhang MD6 | Tiejun Yuan MS7 | Yanli Tao MS7 | Xun Meng MS6 | Luo Zhang MD, PhD1,3,8
Chengshuo Wang MD1

1Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
2Department of Otolaryngology, Head and Neck Surgery, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China
4Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Baotou Capital Medical University, Inner Mongolia, China
5Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Dalian Medical University, Liaoning, China
6Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of JinNan University, Guangdong, China
7Department of Otolaryngology, Head and Neck Surgery, Weifang People’s Hospital, Shandong, China
8Key Laboratory of Otolaryngology, Head and Neck Surgery, Ministry of Education, Beijing Institute of Otolaryngology, Beijing, China

Correspondence
Luo Zhang, Beijing Institute of Otolaryngology, No. 17, Houguo Hutong, DongCheng District, Beijing 100005, China.
Email: dr.luozhang@139.com;
Chengshuo Wang, Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Email: wangcs830@126.com

Funding information
National key R&D program of China, Grant/Award Number: 2016YFC2016090520;
Changjiang scholars and innovative research team, Grant/Award Number: IRT13082;
National natural science foundation of China, Grant/Award Number: 81420108009, 81630023, 81400444 and 81470678; Beijing Municipal Administration of Hospitals’ Mission Plan, Grant/Award Number: SML20150203; Beijing Municipal Administration of Hospitals’ Youth Programme, Grant/Award Number: QML20150202; Beijing advanced innovation center for food nutrition and human health (Beijing Technology and Business University), Grant/Award Number: 20181045; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, Grant/Award Number: XMLX201816; Capital Health Development Foundation, Grant/Award Number: 2016-1-2052

Abstract

Background: We aimed to assess the recurrence risk of sinonasal inverted papillomas (SNIPs), based on a staging system developed according to the originating site of SNIP.

Methods: A total of 200 patients with SNIP were enrolled, and a staging system was developed based on the originating sites and corresponding recurrence rates of tumor in the patients. In the verification phase, 675 patients with SNIPs were enrolled as above, and the originating sites of the SNIPs were confirmed by an endoscopic sinus surgery. Cluster analysis was performed to determine the stage for each SNIP.

Results: Overall, 608 patients completed the study. SNIP recurrence rates for stages 1-4 were 0 (n = 43), 4.0% (n = 420), 13.4% (n = 134), and 36.4% (n = 11), respectively (total = 6.4%).

Conclusions: The origin site-based classification of SNIP may aid surgeons in selecting appropriate endoscopic surgical approaches to minimize the risk of recurrence.

Keywords
endoscopy, recurrence, sinonasal inverted papilloma, staging system, surgical approach

†Yifan Meng and Gaoli Fang contributed equally to this study.
1 | INTRODUCTION

Sinonasal inverted papilloma (SNIP) is a type of benign tumor located in the sinonasal area.\(^1\) It arises in the Schneiderian epithelium and represents 0.5%-4% of all sinonasal tumors.\(^2,3\) A SNIP, however, has the potential for malignant transformation, with some studies reporting a malignancy rate of about 10%-4.5%.\(^4,5\) Despite the malignancy, a most challenge aspect of SNIP for otolaryngologists is the high recurrence rate of this entity.\(^2\) Indeed, several studies have indicated that the recurrence rate of SNIP may range from 10% to 25.3%.\(^6,8\) Although endoscopic surgery is the gold standard for the treatment of SNIP, the major factor associated with recurrence appears to be the incomplete initial resection of the SNIP,\(^2,9\) particularly as most SNIP recur at the same site from which the tumor originated.\(^5,10\) Thus, identification of the origin site of a SNIP before surgery and complete resection of the original location and surrounding area of the tumor are important for preventing or reducing the risk of recurrence after surgical intervention.\(^10\)

The identification of the origin site of SNIP is essential for the management of this tumor, which sometimes has a small narrow pedicle or attachment.\(^11\) With the development of endoscopic sinus surgery (ESS), CT, and MRI, it is now possible to trace the original site of the tumor, regardless of the tumor size.\(^11\) Although Chawla et al.\(^12\) have demonstrated that the osteitis sign and neoosteogenesis on the CT scans could be used to identify the site of attachment of the SNIP, Fang et al.\(^10\) have indicated that preoperative MRI may provide a better option to accurately predict the original site of the SNIP than CT, and thus may facilitate accurate and complete removal of the SNIP.\(^10\)

Staging is important in prognosis of the disease\(^9\) and in achieving a satisfactory surgical outcome.\(^11\) In this regard, several different SNIP staging systems have been reported and commonly used over the last few decades.\(^13-16\) Almost all the published staging systems to date have been based on tumor volume,\(^1\) and based on this logic, a larger tumor has often meant higher staging and higher recurrence risk. However, Kim et al.\(^11\) have demonstrated that there was no significant difference between SNIP recurrence rate and clinical stage based on different staging systems, including the Krouse staging system,\(^13\) Furuta staging system,\(^17\) and Citardi staging system.\(^16\) Although some studies have recommended staging the SNIP based on the original site of the tumor rather than the tumor volume,\(^11,18,19\) none of the SNIP staging systems reported in recent years were shown to accurately associate recurrence rates according to SNIP stages.\(^13-16\) The aim of this study was to assess the recurrence risk associated with different SNIP origin sites and establish an ESS staging system based on the SNIP origin site.

2 | PATIENTS AND METHODS

2.1 | Patients and study design

Patients diagnosed with SNIP based on MRI findings, as we have described earlier,\(^10\) and histopathological evaluation of biopsy samples were enrolled from 6 centers across China. All centers used the same diagnostic and preoperative procedures for the assessment of eligible patients with SNIP, and patients with tumors demonstrating malignant transformation were excluded because the therapeutic strategy would be altered accordingly. Before surgery, the demographic characteristics of each patient and the origin and affected sites with SNIP were recorded. The surgical approaches and the exact origin and involved sites of the tumor were recorded, and all the patients were followed up for at least 36 months, during which period SNIP recurrence times and recurrence rates were recorded.

This study was approved by the ethics committees of the 6 participating centers: Beijing TongRen Hospital, Beijing Ditan Hospital, The Second Affiliated Hospital of Baotou Capital Medical University, The First Affiliated Hospital of Dalian Medical University, The First Affiliated Hospital of JiNan University, and Weifang People's Hospital; and conducted in accordance with the ethical standards of the committee on human experimentation of the institution or in accordance with the Helsinki Declaration of 1975 as revised in 1983. All patients were given the relevant study information and instructions necessary for inclusion in the study, and all patients provided written informed consent before entering into the study.

2.2 | Staging system

2.2.1 | Developmental phase

Preliminary investigations were conducted in 200 patients with SNIP, who underwent ESS in the 6 designated study centers from March 2000 to March 2007. The originating and involved sites of SNIP predicted by MRI evaluation\(^10\) were confirmed by the surgical procedure, and the patients were followed up for a minimum of 36 months, during which period the patients were evaluated for recurrence of the SNIP. Retrospective analysis of data obtained from this cohort indicated that the SNIP recurrence rates were different according to the site from which the tumor originated. Thus, when the tumor originated from a location that was easy to access—for example, the nasal cavity, ethmoid sinus, posterior-lateral and superior wall of the maxillary sinus—the rates of recurrence were low (less than 10%). However, when the tumor originated from a location that was more difficult to access—such as lateral partial of frontal sinus—the recurrence rate was significantly increased (50% in this cohort). In view of this finding, we summarized 10 anatomic regions according to different originating site and difficulty of accessing and then performed cluster...
analysis based on the recurrence rate. This analysis indicated 4 clusters (Figure 1), including cluster 1: ethmoid sinus (except supraorbital ethmoid cell), posterolateral or superior wall of the maxillary sinus, sphenoid sinus (except lateral recess of sphenoid sinus), frontal sinus (facial midline to lamina papyracea); cluster 2: superior sinus (facial midline to lamina papyracea); cluster 3: nasal cavity; and cluster 4: frontal sinus (lateral of central pupil).

Based on these clusters, we further categorized a SNIP into 4 stages as follows: stage 1 (cluster 3): the region that was easiest to access with an endoscope and the surgeon could resect the tumor directly without further sinusotomy; stage 2 (cluster 2): anatomic regions that were easy to access and sinusotomy was necessary for resecting the tumor origin site; stage 3 (cluster 1): anatomic regions that were difficult to access even after sinusotomy, and the surgeon needed to adopt a specialized endoscopic approach; stage 4 (cluster 4): anatomic regions that were scarcely possible to access using an endoscopic approach (such as far corner of frontal sinus), and therefore ESS in combination with an external approach was recommended (Table 1 and Figure 2).

2.2.2 Verification phase

To verify this staging system, we performed a prospective multicenter study involving 675 patients with SNIP enrolled from the same 6 designated hospitals in China, from March 2010 to February 2015. The originating sites of SNIP were evaluated by surgery, using standardized experimental and surgical approaches in all the centers, and staged accordingly (Table 1). In particular, for the SNIPs with originating site included in stage 1 or stage 2, the surgeons used standard ESS to excise the tumor. Similarly, in stage 3, for tumors originating from superior orbital cell, the ESS-assisted Draf IIb approach plus lamina papyracea resection was used; for tumors originating from inferior, anterior, or medial wall of the maxillary sinus, the ESS-assisted prelacrimal duct approach was used; for tumors originating from sphenoid sinus (lateral of Sternberg line), the ESS-assisted pterygoid process approach was used; for tumors originating from ethmoid sinus (except superior orbital cell); MS1, posterior, lateral, or superior wall of the maxillary sinus; SS1, sphenoid sinus (medial of Sternberg's canal); ES1, ethmoid sinus (except superior orbital cell); ES2, superior orbital cell; MS2, inferior, anterior, or medial wall of the maxillary sinus; SS2, sphenoid sinus (lateral of Sternberg's canal or affected bilateral sinus); FS1, frontal sinus (lateral of central pupil) (Table 1 and Figure 2).

2.3 Statistical analysis

Hierarchical clustering method was performed using SPSS 22.0 (SPSS Inc., Chicago, Illinois), the different origin site of tumor and corresponding recurrence rate were enrolled in the statistical model, and the result was rendered as a cladogram. Chi-square or Fisher's exact test was used to analyze recurrences rates, and the results were considered statistically significant at $P < .05$. GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, California) was used for survival analyses. Survival was calculated using the Kaplan-Meier method and curves compared using Mantel-Haenszel test (log rank). End points were calculated from the date of diagnosis until recurrence.

3 RESULTS

A total of 608 of 675 patients (531 men, 77 women; mean age 49.9 ± 4.5 years) completed the study, with a mean follow-up time of 60.3 ± 2.7 months. The total recurrence rate was 6.4%, with recurrence rates of 0, 4.0%, 13.4%, and 36.4% for stages, 1, 2, 3, and 4 tumors, respectively (Table 2).

Based on the current staging system, in stage 1, the tumor originated from the nasal cavity in 43 cases, whereas in stage 2, the tumor originated from maxillary sinus in 97 cases (23.1%), from ethmoid sinus in 255 cases (60.7%), from frontal sinus in 38 cases (9.0%), and from sphenoid
snail in 30 cases (7.1%) (Table 2). Similarly, in stage 3, the tumor originated from maxillary sinus in 72 cases (53.7%), from frontal sinus in 29 cases (21.6%), from sphenoid sinus in 19 cases (14.2%), and from superior orbital cell in 14 cases (10.4%), whereas 11 cases of tumor originating from lateral partial of frontal sinus were noted in stage 4 (Table 2). Overall, ethmoid sinus (44.2%) and maxillary sinus (27.8%) were most affected, followed by frontal sinus (12.8%) and sphenoid sinus (8.1%), according to our staging system (Table 1). Assessment according to the Krouse staging system also demonstrated that SNIP originated mostly in ethmoid sinus (41.8%) and maxillary sinus (29.1%) were also most involved, followed by frontal sinus (11.7%) and sphenoid sinus (10.7%) (Table 3).

The survival analysis for the study cohort is shown in Figure 3. The estimated recurrence-free survival rates (mean [95% confidence interval]) from stages 1, 2, 3, and 4 after surgery were 100%, 96.0% (92.4%-98.1%), 86.6% (83.1%-94.7%), and 63.6% (56.7%-70.7%), respectively. Representative MRI/CT scans and nasal endoscopic examination images of SNIP origin in individual patients at different stages, before and after surgery using different surgical approaches based on the staging of the tumors, are shown in Supporting Information Suppl. Figures 1-6.

**TABLE 1**  The sinonasal inverted papilloma staging system and recommended surgical approach

| Classification based on the originating site | Recommended surgical approach |
|---------------------------------------------|--------------------------------|
| Stage 1                                     | Nasal cavity                   |
| Stage 2                                     | Ethmoid sinus (except superior orbital cell) | ESS (simple tumor resection) |
| Stage 3                                     | Superior orbital cell          | ESS-assisted endonasal approach (ie, Draf IIb approach plus lamina papyracea resection) |
| Stage 4                                     | Frontal sinus (lamina papyracea to central pupil or invading bilateral sinus) | ESS with combined external approach |
| Abbreviation: ESS, endoscopic sinus surgery. |

**DISCUSSION**

SNIP is a common tumor, with a high recurrence rate ranging from 10% to 25.3%. It has been suggested that the risk of recurrence of SNIP is likely to be a consequence of incomplete surgical resection, rather than due to specific characteristics of the tumor itself, particularly because most SNIP recur at the same site where the tumor originated. Thus, the concept of SNIP resection has changed from aggressive surgery to pedicle-oriented endoscopic surgery. However, some studies have recommended routine endoscopic surgery combined with an advanced endonasal approach or external approach, because some sites of the tumor origin were located in anatomic areas, which were hard to access by endoscopy alone.

In this study, we performed a retrospective cluster analysis of data from a preliminarily investigation involving a cohort of 200 patients with SNIPs from 6 centers and developed a staging system for assessment of SNIP recurrence risk and appropriate surgical approach recommended, based on the originating site of the tumor. Treatment of patients using surgical approaches recommended according to this staging system in a subsequent prospective multicenter study involving 675 SNIP patients demonstrated a total recurrence rate of 6.4% for this cohort, which was much lower compared with several earlier large sample studies. Moreover, our study demonstrated that the recurrence rate increased and conversely the estimated recurrence-free survival rate decreased, with increasing order of SNIP staging. However, in accordance with findings from other studies, our study also demonstrated that SNIP originated mostly in ethmoid sinus (44.2%), followed by maxillary sinus (27.8%), frontal sinus (12.8%), and sphenoid sinus (8.1%). Furthermore, these results were comparable with those noted using the Krouse staging system.

In the case of the 43 patients in stage 1, none had recurrence, likely because the tumor originating in the nasal cavity (nasal septum or inferior turbinate) could be observed readily using 0° endoscopy and the tumor pedicle resected completely (Supporting Information Suppl. Figure 1). In the case of 255 patients in stage 2 with tumors originating in the ethmoid sinus (except superior orbital cell); the tumors in 184 of these patients originated from the anterior ethmoid sinus and in the remaining patients from the posterior ethmoid sinus. However, regardless of location of the tumor origin in the ethmoid sinus, the total recurrence rate was low, possibly because, similar to stage 1 tumor, the tumor origin site and pedicle...
of SNIP could easily be visualized\(^5\) using \(0^\circ\) endoscopy or angle endoscopy, and sinusotomy and complete resection of the tumor pedicle achieved successfully. Furthermore, the tumor origin sites in the nasal cavity or ethmoid sinus (except superior orbital cell) were easy to follow up after surgical intervention for signs and
symptoms of recurrence, such as nasal obstruction and epistaxis, and administration of appropriate timely treatment.\textsuperscript{5,11} In this regard, tumors originating from superior orbital cell were an exception. Thus, in the case of 14 patients with tumors originating from the superior orbital cell in this study, there was recurrence in 2 of these patients; which led to significantly greater recurrence rate than for tumors originating from the ethmoid sinus (\(P < .05\)). However, as the tumor originating site was sometimes located at the most distal part of the superior orbital cell, partial resection of the lamina papyracea and displacement of the eye ball to the outside to identify the originating site of the SINP for resection were necessitated. Thus, although the superior orbital cell belongs to anterior ethmoid sinus, in this study a SNIP in this area was categorized as stage 3.

Similarly, there were 169 patients with SNIPs originating from the maxillary sinus, with tumors in 97 patients originating from lateral, posterior, or superior wall of the maxillary sinus and tumors in the remaining 72 patients originating from inferior, anterior, or medial wall of the maxillary sinus. In the case of patients with tumors originating from lateral, posterior, or superior wall of the maxillary sinus, these were categorized as stage 2, because tumor resection could be achieved more easily through maxillary sinus ostium using 0° endoscopy or angle endoscopy, and with a reduced recurrence rate (Supporting Information Suppl. Figure 2). However, in the case of patients with the tumors originating from inferior, anterior, or medial wall of the maxillary sinus, these were categorized as stage 3, because it was difficult to observe the tumor’s originating site due to the acute angle, even using 70° endoscopy. Indeed, the recurrence rate was significantly higher in these groups of stage 3 patients compared with their counterpart stage 2 patients (11.1% vs 3.1%; \(P < .05\)). Thus, in view of this finding, we recommended that for patients with tumor originating from inferior, anterior, or medial wall of the maxillary sinus, ESS-assisted pre-lacrimal duct approach should be used to manage the SNIP more directly and easily (Supporting Information Suppl. Figure 3), as demonstrated by Suzuki and colleagues.\textsuperscript{23} Indeed, several studies have suggested that ESS-assisted pre-lacrimal duct approach was a safe and effective method for resecting SNIP from maxillary sinus with low recurrence rate.\textsuperscript{11,23,24} Furthermore, the use of this technique may avoid the sacrifice of the inferior turbinate and other intranasal anatomic structures, thereby reducing the possibility of further abnormal physiological effects.\textsuperscript{24}

The management of SNIP originating from the frontal sinus is the most challenging due to the narrow space, the anatomically variable frontal recess, and the proximity to the orbital tissue and anterior skull base.\textsuperscript{25} In this study, we divided the frontal sinuses into 3 zones according to facial midline, lamina papyracea, and central pupil (Figure 2E,J,K, L). When the SNIP originated from facial midline to lamina papyracea, sinusotomy and tumor resection were relatively easier, and this was categorized as stage 2. However, when

### TABLE 2
The characteristics of different stage

|                | Stage 1 | Stage 2 | Stage 3 | Stage 4 | \(P\) value |
|----------------|---------|---------|---------|---------|-------------|
| Case           | 43      | 420     | 134     | 11      | NS          |
| Age (mean ± SD), years | 45.7 ± 7.4 | 50.7 ± 7.1 | 50.0 ± 4.3 | 53.1 ± 3.8 | NS          |
| Sex (M/W)      | 29/14   | 381/39  | 113/21  | 8/3     | <.001       |
| Recurrence cases (%) | 0 (0)   | 17 (4.0) | 18 (13.4) | 4 (36.4) | <.01        |

Abbreviations: M, men; W, women.

### TABLE 3
SNIP originating site located in sinuses based on the staging system employed

| Classification based on: | Krouse Classification\textsuperscript{13} (%) |
|--------------------------|---------------------------------------------|
| SNIP originating site (%) |                                             |
| Stage 1                  | 43 cases                                    |
| 97 in maxillary sinus (23.1) | 322 cases                                   |
| 255 in ethmoid sinus (60.7) | 68 in maxillary sinus (21.1)               |
| 38 in frontal sinus (9.0)  | 254 in ethmoid sinus (78.9)                |
| 30 in sphenoid sinus (7.1) |                                             |
| Stage 2                  | 420 cases                                    |
| 72 in maxillary sinus (53.7) | 245 cases                                   |
| 29 in frontal sinus (21.6)  | 109 in maxillary sinus (44.5)               |
| 19 in sphenoid sinus (14.2) | 71 in frontal sinus (29.0)                  |
| 14 in superior orbital cell (10.4) | 65 in sphenoid sinus (26.5)               |
| Stage 3                  | 134 cases                                    |
| 21 in frontal sinus (16.6)  |                                             |
| 19 in sphenoid sinus (14.2) |                                             |
| 14 in superior orbital cell (10.4) |                                             |
| Stage 4                  | 11 cases                                     |
| 11 in frontal sinus       | 18 cases                                     |
|                           |                                             |

### FIGURE 3
Survival analysis of the study cohort. The recurrence-free survival rates of stages 1-4 were 100% (black line), 96.0% (92.4%-98.1%, pink line), 86.6% (83.1%-94.7%, blue line), and 63.6% (56.7%-70.7%, red line), respectively (95% confidence interval, \(P < .05\))
the tumor originated from lamina papyracea to central pupil or invaded bilateral frontal sinus, the originating sites in these areas were difficult to observe due to the acute angle, and these were categorized as stage 3. For these types of SNIP, we recommend the use of Draf Iib plus lamina papyracea resection approach or ESS-assisted Draf III approach (Supporting Information Suppl. Figure 5). Zhang et al.,21 and Takahashi et al.,25 have suggested that the Draf III surgical approach allows good visualization of a tumor’s originating site and should therefore be used to treat SNIP because it can avoid facial destruction.

In this study, 11 patients were seen with SNIPs located in lateral of central pupil, which required an ESS-combined external approach for excision, and were therefore categorized as stage 4. The overall tumor recurrence rate for this stage was significantly higher compared to the other stages; with 4 of these patients (36.4%) experiencing recurrence. The SNIP patients in this stage always demonstrated either one or both very well-pneumatized frontal sinuses, which were beyond the same side vertical line of central pupil. For SNIP originating site located in this area, it was rarely possible to achieve complete endonasal pedicle resection using even the Draf III approach, because of the difficulty in accessing the site with the forceps or microdebrider; thus in such cases, we recommend the use of ESS with a combined external approach (Supporting Information Suppl. Figure 6). This finding is in accordance with the findings of Timperley et al.,27 who assessed endoscopic access to the frontal sinus in 10 cadaver heads. The authors divided the unilateral frontal sinus into 4 zones, of which zone 1 comprised the medial quarter, zone 2 from zone 1 to the midorbital point, zone 3 from zone 2 to halfway between the midorbital point and the lateral aspect of the orbit, and zone 4 comprised the lateralmost quarter. In this regard, zones 1 and 2 were comparable to stage 3, and zones 3 and 4 were comparable to stage 4 in this study. The authors demonstrated that although the frontal sinus zones 1 and 2 could be accessed completely using the Draf III approach, only 10% of the orbital roofs in the lateral partial of frontal sinus (zones 3 and 4) were accessible using this approach and ancillary external approaches may be required for surgery in these areas.27 Similarly, other studies have also suggested that when the tumor was located in the lateral of frontal sinus, ESS with combined external approach was indicated and had lower tumor recurrence rate.17,28,29

In accordance with other studies,5,9 this study has also demonstrated that the sphenoid sinus is the least affected, with only 49 patients (8.1%) demonstrating a SNIP in this area. We found that some patients had well-pneumatized sphenoid sinus lateral recess and therefore required different endonasal approaches according to the different locations of tumor originating sites in the sphenoid. Thus, the unilateral sphenoid sinus was divided into medial part and lateral recess of the sphenoid sinus, and similar to frontal sinus, when the SNIP originated close to the medial part of sphenoid sinus (stage 2), tumor resection was recommended using 0° endoscopy or angle endoscopy. However, when the tumor originated in lateral recess of the sphenoid sinus (stage 3), ESS-assisted pterygoid process approach was recommended due to the challenges posed by the presence of closely situated vital structures such as the optic nerve and the carotid artery.30 Although one study has suggested that endonasal pterygoid process approach could take advantage of the vidian nerve to locate the position of foramen lacerum of the internal carotid artery,31 another study has set up a classification to help to understand anatomy of pterygoid area to achieve endoscopic endonasal transpterygoid approach.32 In this study, 9 tumors were found to break through the sphenoid sinus septum and invade bilateral sphenoid sinus (stage 3, Supporting Information Suppl. Figure 4). Thus, ESS-assisted sphenoidal rostrum process approach was performed to resect the sphenoid sinus septum and then integrate bilateral sphenoid sinuses.

5 | CONCLUSION

Incomplete surgical resection of the originating site of a SNIP is the most important risk factor of recurrence and thus the development of a SNIP staging system associated with recurrence rate based on the originating site of tumor was the main focus of this study. The origin site-based classification of SNIP we have developed is easy to understand and demonstrates a good correlation between the SNIP stage and recurrence rate. It is possible that identification of the originating site of a SNIP before or during a surgical intervention may aid surgeons to select appropriate endoscopic surgical approaches recommended according to the staging system, thereby minimizing the risk of recurrence.

CONFLICT OF INTEREST

The authors declare that they have no financial or personal relationships with persons or organizations that can inappropriately influence their work. Furthermore, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of this manuscript.

ORCID

Luo Zhang https://orcid.org/0000-0002-0910-9884

REFERENCES

1. Buchwald C, Nielsen LH, Nielsen PL, Ahlgren P, Tos M. Inverted papilloma: a follow-up study including primarily unacknowledged cases. Am J Otolaryngol. 1989;10:273-281.
2. Kim JY, Kwon SH. Recurrence of sinonasal inverted papilloma following surgical approach: a meta-analysis. Laryngoscope. 2017;127(1):52-58.
3. Lawson W, Ho BT, Shaari CM, Biller HF. Inverted papilloma: a report of 112 cases. Laryngoscope. 1995;105:282-288.
4. Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS. Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. *J Laryngol Otol*. 2007;121:857-864.

5. Krouse JH. Endoscopic treatment of inverted papilloma: safety and efficacy. *Am J Otolaryngol*. 2001;22:87-99.

6. Busquets JM, Hwang PH. Endoscopic resection of sinonasal inverted papilloma: a meta-analysis. *Otolaryngol Head Neck Surg*. 2006;134(3):476-482.

7. Peng P, Har-El G. Management of inverted papillomas of the nose and paranasal sinuses. *Am J Otolaryngol*. 2006;27:233-237.

8. Nygren A, Kiss K, von Buchwald C, Bilde A. Rate of recurrence and malignant transformation in 88 cases with inverted papilloma between 1998–2008. *Acta Otolaryngol*. 2016;136:333-336.

9. Lisan Q, Laccourreye O, Bonfils P. Sinonasal inverted papilloma: risk factors for local recurrence after surgical resection. *Ann Otol Rhinol Laryngol*. 2017;126(6):498-504.

10. Fang G, Lou H, Yu W, et al. Prediction of the originating site of sinonasal inverted papilloma by preoperative magnetic resonance imaging and computed tomography. *Int Forum Allergy Rhinol*. 2016;6:1121-1128.

11. Kim DY, Hong SL, Lee CH, et al. Inverted papilloma of the nasal cavity and paranasal sinuses: a Korean multicenter study. *Laryngoscope*. 2012;122:487-494.

12. Chawla A, Shenoy J, Chokkappan K, Chung R. Imaging features of sinonasal inverted papilloma: a pictorial review. *Curr Probl Diagn Radiol*. 2016;45(5):347-353.

13. Krouse JH. Development of a staging system for inverted papilloma. *Laryngoscope*. 2000;110(6):965-968.

14. Han JK, Smith TL, Loehr T, Toohill RJ, Smith MM. An evolution in the management of sinonasal inverting papilloma. *Laryngoscope*. 2001;111(8):1395-1400.

15. Kamel R, Khaled A, Kandil T. Inverted papilloma: new classification and guidelines for endoscopic surgery. *Am J Rhinol*. 2005;19(4):358-364.

16. Cannady SB, Batra PS, Sautter NB, Roh H-J, Citardi MJ. New staging system for sinonasal inverted papilloma in the endoscopic era. *Laryngoscope*. 2007;117(7):1283-1287.

17. Oikawa K, Furuta Y, Nakamura Y, Oridate N, Fukuda S. Preoperative staging system and surgical approaches for sinonasal inverted papilloma. *Ann Otol Rhinol Laryngol*. 2007;116:674-680.

18. Lee TJ, Huang SF, Lee LA, Huang CC. Endoscopic surgery for recurrent inverted papilloma. *Laryngoscope*. 2004;114:106-112.

19. Landsberg R, Cavel O, Segev Y, Khafif A, Fliss DM. Attachment-oriented endoscopic surgical strategy for sinonasal inverted papilloma. *Am J Rhinol*. 2008;22:629-634.

20. Myers EN, Schramm VL Jr, Barnes EL Jr. Management of inverted papilloma of the nose and paranasal sinuses. *Laryngoscope*. 1981;91:2071-2084.

21. Zhang L, Han D, Wang C, Ge W, Zhou B. Endoscopic management of the inverted papilloma with attachment to the frontal sinus drainage pathway. *Acta Otolaryngol*. 2008;128:561-568.

22. Jiang XD, Dong QZ, Li SL, Huang TQ, Zhang NK. Endoscopic surgery of a sinonasal inverted papilloma: surgical strategy, follow-up, and recurrence rate. *Am J Rhinol Allergy*. 2017;31:51-55.

23. Suzuki M, Nakamura Y, Yokota M, Ozaki S, Murakami S. Modified transnasal endoscopic medial maxillectomy through prelacrimal duct approach. *Laryngoscope*. 2017;127:2205-2209.

24. Wang C, Han D, Zhang L. Modified endoscopic maxillary medial sinusotomy for sinonasal inverted papilloma with attachment to the anterior medial wall of maxillary sinus. *Otol J Otorhinolaryngol Relat Spec*. 2012;74(2):97-101.

25. Takahashi Y, Shoji F, Katori Y, et al. Endoscopic surgical management of sinonasal inverted papilloma extending to frontal sinuses. *Otolaryngol Pol*. 2016;70(6):26-31.

26. Gras-Cabrerozo JR, Montserrat-Gili JR, Massegur-Solench H, León-Vintró X, DeJuan J, Fabra-Llopis JM. Management of sinonasal inverted papillomas and comparison of classification staging systems. *Am J Rhinol Allergy*. 2010;24:66-69.

27. Timperley DG, Banks C, Robinson D, Roth J, Sacks R, Harvey RJ. Lateral frontal sinus access in endoscopic skull-base surgery. *Int Forum Allergy Rhinol*. 2011;1(4):290-295.

28. Sciarretta V, Fernandez JJ, Farneti P, Pasquini E. Endoscopic and combined external-transnasal endoscopic approach for the treatment of inverted papilloma: analysis of 110 cases. *Ear Arch Otorhinolaryngol*. 2014;271:1953-1959.

29. Walgama E, Ahn C, Batra PS. Surgical management of sinus inverted papilloma: a systematic review. *Laryngoscope*. 2012;122(6):1205-1209.

30. Suh JD, Ramakrishnan VR, Thompson CF, et al. Inverted papilloma of the sphenoid sinus: risk factors for disease recurrence. *Laryngoscope*. 2015;125:544-548.

31. Wang X, Yu H, Cai Z, et al. Anatomical study on Meckel cave with endoscopic endonasal, endo-maxillary sinus, and endo-pterygoid process approaches. *PLoS One*. 2014;9(3):e91444.

32. Kasemsiri P, Solares CA, Carrara RL, et al. Endoscopic endonasal transpterygoid approaches: anatomical landmarks for planning the surgical corridor. *Laryngoscope*. 2013;123:811-815.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article**: Meng Y, Fang G, Wang X, et al. Origin site-based staging system of sinonasal inverted papilloma for application to endoscopic sinus surgery. *Head & Neck*. 2019;41:440–447. [https://doi.org/10.1002/hed.25435]